BFM
CELZ icon

Boothbay Fund Management’s Creative Medical Technology CELZ Stock Holding History

Boothbay Fund Management’s Portfolio CELZ Stock Details CELZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-4,000
Closed -$15.2K – 2165
2022
Q4 		$15.2K Sell
4,000
-4,889
-55% -$20.1K ﹤0.01% 1925
2022
Q3 		$39K Hold
8,889
– – ﹤0.01% 2131
2022
Q2 		$67K Buy
+8,889
New +$143K ﹤0.01% 2047

Other funds holding CELZ

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Boothbay Fund Management's CELZ Position: Q1 2023 in Review

Boothbay Fund Management sold out of Creative Medical Technology (CELZ) in Q1 2023, closing a stake of 4,000 shares — an estimated $15.2K sold.

Boothbay Fund Management first reported a position in CELZ in Q2 2022 and held it in 3 quarters. The position peaked at $67K in Q2 2022. 15 funds tracked by Wall St. Rank hold CELZ as of Q1 2023.

  • Boothbay Fund Management reported no remaining Creative Medical Technology position as of Q1 2023 after selling out during the quarter.
  • Boothbay Fund Management sold 4,000 Creative Medical Technology shares in Q1 2023, an estimated $15.2K.
  • Boothbay Fund Management first reported a position in Creative Medical Technology in Q2 2022 and held it in 3 quarters.
  • Boothbay Fund Management's Creative Medical Technology position peaked at $67K in Q2 2022.
  • 15 funds tracked by Wall St. Rank held Creative Medical Technology as of Q1 2023.

Based on Boothbay Fund Management's 13F filing for Q1 2023, filed 15 May 2023.